This Study Will Evaluate the Safety, Tolerability, and Efficacy of ANB032 in Subjects with Moderate to Severe Atopic Dermatitis (AD).

NCT05935085 · clinicaltrials.gov ↗
PHASE2
Phase
TERMINATED
Status
201
Enrollment
INDUSTRY
Sponsor class

Stopped ANB032 did not meet the primary endpoint in moderate-to-severe atopic dermatitis

Conditions

Interventions

Sponsor

AnaptysBio, Inc.